Nicholas A Saccomano insider trades

Open-market stock purchases and sales by Nicholas A Saccomano, President and CEO at OnKure Therapeutics, Inc, from SEC Form 4 filings since Aug 18, 2014.

Recent trades

DateStockTradeValue
Sep 21, 2026OKUR OnKure Therapeutics, IncSold$259
Aug 7, 2026OKUR OnKure Therapeutics, IncBought (not open market)—
Aug 7, 2026OKUR OnKure Therapeutics, IncSold (not open market)$50K
Aug 7, 2026OKUR OnKure Therapeutics, IncBought (not open market)$9.8K
Aug 7, 2026OKUR OnKure Therapeutics, IncSold (not open market)$20.8K
Aug 7, 2026OKUR OnKure Therapeutics, IncBought (not open market)$6.1K
Aug 7, 2026OKUR OnKure Therapeutics, IncSold (not open market)$118K
Aug 7, 2026OKUR OnKure Therapeutics, IncBought (not open market)$35K
Aug 7, 2026OKUR OnKure Therapeutics, IncSold (not open market)$236K
Aug 7, 2026OKUR OnKure Therapeutics, IncBought (not open market)$70K
Aug 7, 2026OKUR OnKure Therapeutics, IncSold (not open market)$9.9M
Aug 7, 2026OKUR OnKure Therapeutics, IncBought (not open market)$2.2M
Jun 22, 2026OKUR OnKure Therapeutics, IncSold$378
Apr 1, 2026OKUR OnKure Therapeutics, IncBought (not open market)—
Mar 23, 2026OKUR OnKure Therapeutics, IncSold$357
Dec 22, 2025OKUR OnKure Therapeutics, IncSold$258

Companies traded

  • OKUR OnKure Therapeutics, Inc: 8 sales, last Sep 21, 2026
  • ARRY Array Biopharma Inc: 1 sale, last Jul 30, 2019

Get free alerts when Nicholas A Saccomano files a new trade →